Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sentinel For Biosimilars? Biologics Post-Market Monitoring Is Focus Of New Consortium

Executive Summary

Group of sponsors, insurers and health systems will draw on datasets of de-identified pharmacy and medical claims data to monitor effectiveness and safety of novel biologics and their corresponding biosimilars.

You may also be interested in...



Biosimilar Suffixes Appear Superfluous In Adverse Event Reporting

Nearly all adverse event reports received by US FDA include brand name of biosimilar, raising questions as to whether suffix on nonproprietary name is necessary for pharmacovigilance.

Biosimilar Suffixes Appear Superfluous In Adverse Event Reporting

Nearly all adverse event reports received by US FDA include brand name of biosimilar, raising questions as to whether suffix on nonproprietary name is necessary for pharmacovigilance.

Biosimilar Suffix Detractors Hope Private Studies Build Their Case

Consortium’s biosimilar pharmacovigilance could provide data foundation to pressure FDA that suffixes are not needed in non-proprietary names.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS057487

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel